Valisure’s CEO, David Light, was invited to participate in the ​Industry Studies Association (ISA) Webinar on Improving the Safety, Security, Robustness, and Resilience of the Nation’s Drug Supply Chain on October 6, 12-2 pm ET.

Led by the U.S. Department of Health and Human Services, one of the Biden Administration’s supply chain reviews released in June 2021 assessed pharmaceuticals and active pharmaceutical ingredients. The review found that the pharmaceutical supply chain is complex, global, and vulnerable to disruptions. The review argued that a robust pharmaceutical supply chain could consistently manufacture high-quality products, is geographically diversified, has redundancy, and has the flexibility to change volumes and products in response to changes in supply and demand. The panel summarized and discussed the results of the HHS-led assessment, from one end of the supply chain (doctor/patient) to the other (key starting materials/active pharmaceutical ingredients).

Moderator: John Gray, Professor, Operations and Business Analytics Department, Fisher College of Business, Ohio State University

Administration Presenter: Elisabeth Reynolds, Special Assistant to the President for Manufacturing and Economic Development, National Economic Council

Discussants:

• Harry Lever, MD, Cardiologist, Cleveland Clinic
• David Light, CEO, Valisure‍
• Eric Edwards, President/CEO, Phlow

Valisure’s CEO, David Light, was invited to participate in the ​Industry Studies Association (ISA) Webinar on Improving the Safety, Security, Robustness, and Resilience of the Nation’s Drug Supply Chain on October 6, 12-2 pm ET.

Led by the U.S. Department of Health and Human Services, one of the Biden Administration’s supply chain reviews released in June 2021 assessed pharmaceuticals and active pharmaceutical ingredients. The review found that the pharmaceutical supply chain is complex, global, and vulnerable to disruptions. The review argued that a robust pharmaceutical supply chain could consistently manufacture high-quality products, is geographically diversified, has redundancy, and has the flexibility to change volumes and products in response to changes in supply and demand. The panel summarized and discussed the results of the HHS-led assessment, from one end of the supply chain (doctor/patient) to the other (key starting materials/active pharmaceutical ingredients).

Moderator: John Gray, Professor, Operations and Business Analytics Department, Fisher College of Business, Ohio State University

Administration Presenter: Elisabeth Reynolds, Special Assistant to the President for Manufacturing and Economic Development, National Economic Council

Discussants:

• Harry Lever, MD, Cardiologist, Cleveland Clinic
• David Light, CEO, Valisure‍
• Eric Edwards, President/CEO, Phlow